Pine Valley Investments Ltd Liability Co Sells 10,535 Shares of Humana Inc. (NYSE:HUM)

Pine Valley Investments Ltd Liability Co cut its position in Humana Inc. (NYSE:HUM) by 85.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,728 shares of the insurance provider’s stock after selling 10,535 shares during the quarter. Pine Valley Investments Ltd Liability Co’s holdings in Humana were worth $549,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in HUM. Pzena Investment Management LLC grew its stake in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock valued at $866,250,000 after buying an additional 1,955,375 shares in the last quarter. Marshall Wace LLP grew its position in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in Humana by 261,025.1% during the 3rd quarter. International Assets Investment Management LLC now owns 738,984 shares of the insurance provider’s stock worth $2,340,660,000 after purchasing an additional 738,701 shares in the last quarter. FMR LLC lifted its holdings in Humana by 23.4% during the 3rd quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after purchasing an additional 643,291 shares in the last quarter. Finally, Baupost Group LLC MA bought a new position in Humana in the 2nd quarter worth about $156,933,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.5 %

Shares of NYSE HUM opened at $274.14 on Friday. The firm’s fifty day moving average is $274.13 and its 200 day moving average is $324.70. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $486.00. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The company has a market cap of $33.01 billion, a price-to-earnings ratio of 24.28, a PEG ratio of 2.15 and a beta of 0.53.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. Humana had a net margin of 1.18% and a return on equity of 13.20%. The company had revenue of $29.30 billion during the quarter, compared to analyst estimates of $28.66 billion. On average, equities research analysts expect that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.29%. Humana’s dividend payout ratio is presently 31.36%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Leerink Partnrs downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Leerink Partners cut shares of Humana from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. JPMorgan Chase & Co. lifted their price objective on Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Finally, Wells Fargo & Company decreased their target price on Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, Humana has an average rating of “Hold” and a consensus price target of $304.15.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.